The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy

NCT01950533 | Completed

• 2 other identifiers: IMMULITE 2000Siemens
• Study Type: observational
• Target: 102
• Locations: 1 country
• Sites: 1

Brief Summary

Food allergy is on the rise within the pediatric population. Having food allergy can cause medical, nutritional and psychological issues in those who suffer with it. Although making the appropriate diagnosis of food allergy is very important, properly diagnosing food allergy has been a challenge. Skin prick testing and food-specific IgE testing of the blood can give positive results that are false. Currently, Oral Food Challenges are the best way to diagnose a food allergy. Unfortunately, Oral Food Challenges are time consuming and may not be readily available to suspected food allergy sufferers. This study is designed to examine the effectiveness of an allergy-detecting blood test called IMMULITE 2000 manufactured by the study sponsor, Siemens.

Conditions

Peanut Allergy; Milk Allergy; Egg Allergy

Keywords

Peanut allergy; Milk allergy; Egg allergy; Pediatric; Adult; Food allergy

Outcome Measures

Primary Outcomes (1)

• Relationship between food specific IgEs

  To determine the relationship between food-specific IgE to whole proteins of milk, egg, and peanut using the IMMULITE 2000 assay and OFC outcomes.

  approximately 2 weeks

Secondary Outcomes (1)

• Logisitic regression analyses on data

  approximately 2 weeks

Study Arms (3)

Peanut allergic

Subjects allergic to peanuts by oral food challenge

Procedure: Oral food challenge

Milk allergic

Subjects allergic to milk by oral food challenge

Procedure: Oral food challenge

Egg allergic

Subjects allergic to egg by oral food challenge

Procedure: Oral food challenge

Interventions

Oral food challenge PROCEDURE

Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.

Egg allergic; Milk allergic; Peanut allergic

Eligibility Criteria

• Age: 3 Years - 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Study population will be primarily obtained from the pediatric clinic at National Jewish Health from those suspected of egg, milk and/or peanut food allergy.

You may qualify if:

• Age 3 to 21 years of either sex and any race
• Physician-diagnosed food allergy or convincing clinical history of food allergy to milk, egg, and/or peanut AND a Skin prick test positive to milk, egg, and/or peanut (diameter of wheal \> 3 mm or greater than negative control) orOR a detectable serum food-specific IgE level (ImmunoCAP and/or IMMULITE \> 0.35 kUA/L) to milk, egg, and/or peanut
• If no history of clinical reactivity to milk, egg, or peanut, then a positive skin prick test to milk, egg, and/or peanut (diameter of wheal \> 3 mm or greater than negative control) OR a detectable serum food-specific IgE level within the previous 4 months to milk, egg, and/or peanut
• Written informed consent from parent/guardian and assent (when age appropriate).
• Willingness to submit specimen for laboratory serum IgE testing

You may not qualify if:

• Inability to discontinue antihistamines for skin prick testing and OFCs
• Current allergy to placebo ingredient (oat flour) OR reaction to any dose of placebo at the qualifying OFC
• FEV1 value \<80% predicted OR any clinical features of moderate or severe persistent asthma, as defined by the 2007 NHLBI guidelines table for classifying asthma baseline severity (Step 3 or above), at the time of entry into the study
• Use of , and \>high medium daily doses of inhaled corticosteroids, as defined by the 2007 NHLBI guidelines inhaled corticosteroid dosing table (500500 μg/day fluticasone or equivalents for an adult) or a long acting beta-agonist (LABA) to control asthma.
• Asthma requiring either:
• \> 1 hospitalization in the past year for asthma or \> 1 ER visit in the past 6 months for asthma
• History of intubation due to allergies or asthma
• Use of steroid medications (IV, IM or oral) for asthma in the following manners:
• history of daily oral steroid dosing for \>1 month during the past year or
• burst or steroid course/burst in the past 3 months or
• \>2 burst oral steroid courses/bursts in the past year
• History of intubation due to allergies or asthma
• Life-threatening allergic reaction (e.gi.e., respiratory compromise, hypoxia, hypotension, use of epinephrine) to study food(s) (e.g., milk, egg, and/or peanut) within last 1 year
• Diagnosis of active eosinophilic gastrointestinal disease in the past year
• Severe or poorly controlled atopic dermatitis, as assessed by a three-item severity (TIS) score of 6 or greater (see Appendix I)

Sponsors & Collaborators

• National Jewish Health: lead

Study Sites (1)

National Jewish Health

Denver, Colorado, 80206, United States

Location

MeSH Terms

Conditions

Peanut Hypersensitivity; Milk Hypersensitivity; Egg Hypersensitivity; Food Hypersensitivity

Condition Hierarchy (Ancestors)

Nut and Peanut Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Erwin Gelfand, MD

  National Jewish Health

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 23, 2013
• First Posted: September 25, 2013
• Study Start: September 1, 2013
• Primary Completion: March 29, 2017
• Study Completion: March 29, 2017
• Last Updated: October 19, 2020

Record last verified: 2020-10

Locations

US (1)